Pharmacotherapy of Renal Bone Disease Flashcards
PTH + Ca
Increases serum Ca
Vit D + Ca
Increases serum Ca
Calcitonin + Ca
Decrease serum Ca
As you lose nephrons you have
Increased PO4 retention (inhibit Vit D, decreased Ca, stimulate PTH)
Decreased productive of Vit D3
Decreased production of Vit D3
Decrease Ca in GI tract
Stimulated PTH secretion =
Decrease reabsorption of PO4 in proximal tubule
Increased reabsorption of Ca
GFR less than 30
Loss of increase Ca reabsorption and decreased phosphate
Decreased Ca reabsorption and increased phosphate reasborption
Bone resorption maintains Ca levels
PTH levels increase
Secondary hyperparathyroidism ADRs
Altered lipid metabolism, insulin secretion, myocardial and skeletal muscle function, neurologic and immune function
Eryhtropoietic therapy resistance
> 495 pg/mL of hormone associated with
increased sudden death and morbidity and mortality
Corrected Ca X PO4 formula
(4-albumin) X 0.8 + Ca
Soft tissue calcification occurs when Corrected Ca is:
> 70 mg2/dL2
- Want to maintain below 55
Elevated Ca-PO4 is associated with:
Vascular calcification
CVD
Calciphylaxis
Death
Normal Ca =
8.5-10.5
Hypocalcemia
Less than 8.5
Acute hypocalcemia
Neuromuscular - tetany, muscle cramps, laryngeal spasm
CV - prolonged QT interval, decreased myocardial contractility
Chronic hypocalcemia
CNS- depression, anxiety, confusion
Derm - hair loss, groved and brtittle nails, exzema
Causes of hypocalcemia
Intensive care unit pt Elderly, malnourished pts Sodium phosphate as a bowl prep agent Vit D deficiency -ectomy Meds
**What meds causes hypocalcemia?
Bispphosphonates, calcitonin, furosemide, oral phoshporus therapy
Treatment for acute symptomatic hypocalcemia
100-300 mg elemental Ca IV over 5-10 minutes
(CaCl 1g or Cagluconate 2-3g)
Continyous infusion of 0.5-2mg/kg/hr
Calcium should not be infused faster than
60 mg per minutes or severe cardiac dysfunction and ventricular fibrillation
Asymptomatic hypocalcemia treatment
Oral 1-3g/d
Correct underlying cause (replace mg and Vit D)
Vit D3 dose
0.5-3mcg/d
Ergocalciferol dose
50,000 units/d
Hypercalcemia =
> 10.5
Symptoms occur usually when >13
Acute hypercalcemia
Anorexia N/V Constipation Polyuria Polydipsia Nocturia
Hypercalcemic crisis =
> 15
Acute renal insufficiency and obtundation
Can progress to worse
Chronic hypercalcemia
Metastatic calcification
Nephrolithiasis
Chronic renal insufficiency
Meds that cause of hypercalcemia
Vit D analogs
Ca supps
Lithium
Hypercalcemia Treatment
NS 200-300 mL/h Furosemide 40-80 mg IV q1-4h Hemodialysis Calcitonin 4 units/kg SQ or IM every 12 hrs Zoledronate 4-8mg IV given over 5
Bisphosphonate caution
GFR
Causes of hypophosphatemia
Decrease GI absorption (PO4 binder, sucralfate)
Increased urinary excretion (hyperparathyroidism)
Refeeding syndrome
Symptoms of hypophosphatemia
Arrhythmia, muscle fatigue, respiratory failure, myalgias, weakness, irritability, seizure, coma
Severe hypophosphatemia Treatment
PO4 15-30 mmol IV over 3 hr
Asymptomatic hypophosphatemia treatment
Oral PO4 supplementation
Hyperphosphatemia causes
Renal failure
Intracellular phosphate release (tumor lysis syndrome)
Hyperphosphatemia symptoms
Soft tissue calcification
N/V/D
Letahrgy and seizures
Renal osteodystrophy
Restrict PO4 when:
> 4.7 or PTH elevated
Phosphorous range
2.6-4.5
What is the first-line treatment of hypercalcemic, low PTH, or vascular calcification?
Phosphate binders (Non-Ca, non-Mg, non-Al based)
Sevelamar HCl (Renagel)
Lowers LDL, increases HDL
Phosphate binder
Lanthanum carbonate (Fosrenol)
Chewable wafer
Phosphate binder
Stage 3/4 treatment
Ca-based binder first-line
Stage 5 treatment
Primary: Ca or phosphate bind or combo
Calcium based binders should not be used in pts who
are hypercalcemic or have low PTH
In pts with phosphate >7.0 mg/dL,
Al-based binders may be used for
Vitamin D compounds that need to be activated:
Ergocalciferol (VitD2)
Cholecalcifediol (VitD3)
Active Vit D compounds
Calcitriol (VitD3)
Paricalcitol, doxercalciferol
ADRs of VitD
Hypercalcemia
Can aggravate hypophosphatemia
Adynamic bone disease
After starting VitD,
Monitor corrected Ca and PO4
D/c Vit D if hyperCa
Hold VitD therapy, then reduce dose by 50% if:
PTH decreases below target
Ca rises precipitously
Start supplement with VitD if
Less than 30
Start supplement with active VitD if
PTH > target range AND vitD below 30
Stage 3-5 CKD Treatment
Active VitD if PTH progressively increasing and remain persistently higher than limit
Calcimimetics
Inhibitor of CYP2D6
Take with meals
Alternative or adjunct to VitD